|Day Low/High||55.27 / 56.17|
|52 Wk Low/High||49.03 / 86.31|
Contrarians who bought several "dead men walking" retailers have pocketed big gains by defying conventional wisdom.
Rite Aid CEO John Standley faces shareholders's scrutiny after the merger flop.
After a failed merger with Albertsons, Rite Aid faces a difficult time on its own in a changing landscape.
A week of bad news for Ride Aid may be good news for its competitors Walgreens and CVS.
Prime Day 2018 is expected to generate $3.4 billion in sales, according to Coresight Research.
Here's to FANG for once again exciting and enthralling and defying all of the negatives.
Shares were down 8% Thursday.
Amazon's acquisition of PillPack is hitting traditional pharmacies.
These stocks are selling at historically low earnings multiples, but have raised their dividends for decades.
Stocks traded in a different pattern Wednesday, as big tech names dominated.
I know there's plenty of irony to go around for this once great manufacturer to be replaced in the Dow by a drug store chain.
Drugstore giant's charts were showing positive signs even before its inclusion in the Dow Jones Industrial Average.
GE is getting tossed from the index, after 111 consecutive years.
These are the stories pushing futures higher ahead of Wednesday's opening bell.
The drugstore chain's price to fair value has not been this favorable since the Crash of 2008-2009.
Theranos, once a Silicon Valley unicorn promising investors and partners like Walgreens a simple blood-testing solution, is a cautionary tale for biotech investors.
Few companies can match CVS' long-term record and top-quality corporate metrics.
If anyone can sell it to antitrust regulators, T-Mobile CEO John Legere can.
Better-than-expected earnings will help soothe market jitters in the second quarter.
Charts suggest there may be hope for Walgreens bulls.
The keys? Preparation, Discipline and Plan of Action.
Volume and other indicators suggest more weakness ahead.